Precision medicine is poised to transform healthcare, with biobanks being identified as a key enabler to bring it to fruition by 2030 by putting new, extended datasets at the disposal of pharmaceutical researchers and healthcare professionals. — by Marilyn Matz
Marilyn Matz, CEO of Paradigm4, and Zachary Pitluk, Vice President of Life Sciences at Paradigm4, explain why scalable data science platforms are key to supporting integrated analysis of single-cell genomic data sets.
Peptides play important roles in human physiology. They present as intact peptides or can arise from protein degradation. Regardless of the source, peptidomics—the characterization of intact peptides in a biological sample—is fast emerging as an approach to uncover another layer in human health and disease.
Popular opinion is that two big shifts have changed the game for bioinformatics. The first is a technology development—single cell ‘omics—that began just over 10 years ago, the other is a more recent move to a new model of drug discovery that looks to leverage the vast amounts of human
